Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Schering-Plough |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00160251 |
The primary objective of this study is to determine the safe and effective dose range of SCH 503034 in combination with PEG-Intron in adult subjects who have chronic hepatitis C without cirrhosis, and who have failed an adequate course of combination therapy with peginterferon-alfa plus ribavirin. A secondary objective is to explore whether ribavirin provides an additional benefit when combined with PEG-Intron plus SCH 503034.
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis C |
Drug: SCH 503034 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | PEG-Intron/REBETOL vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C HCV-1 Peginterferon Alfa/Ribavirin Nonresponders: A SCH 503034 Dose-Finding Phase 2 Study |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Key inclusion criteria:
Key exclusion criteria:
Study ID Numbers: | P03659 |
Study First Received: | September 8, 2005 |
Last Updated: | July 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00160251 |
Health Authority: | United States: Food and Drug Administration |
PEG-Intron Ribavirin Protease Inhibitor |
Virus Diseases Hepatitis Signs and Symptoms Liver Diseases Digestive System Diseases Hepatitis, Chronic |
Ribavirin Peginterferon alfa-2b Hepatitis, Viral, Human Hepatitis C Interferon Alfa-2b Hepatitis C, Chronic |
Antimetabolites Anti-Infective Agents RNA Virus Infections Molecular Mechanisms of Pharmacological Action |
Flaviviridae Infections Therapeutic Uses Antiviral Agents Pharmacologic Actions |